Sam Parr

I was talking to Kroc and asking him about this.

So there's some pretty cool companies.

I didn't realize, first of all, Google has their own company they spun out from this.

So Isomorphic Labs.

So basically, Google has spun out this company that is...

basically trying to cure all disease.

That's the mission.

No big deal.

And their thought process is like, well, with AI, we can, you know, from first principles, change the way that drug development and discovery works because if we can predict how the proteins fold, then we can...

have a way higher hit rate on the targets we designed with the drugs, then we should be able to simulate if it's going to work with it.

Before we even get to clinical trials, we should be able to run, you know, hundreds of thousands of simulations to see how effective this can be, get the probability of success higher, so that when we enter a trial, we have a way higher hit rate.

And this company, by the way, their first round of funding was $600 million.

as they spun it out of Google and DeepMind.

And Demis is the CEO, I think, of Isomorphic Labs.

And so there's a world where Google becomes the drug company that cures, like right now they're working on malaria and these different things.

If I was doing a Sarah's List episode right now, Isomorphic Labs would be one of those where I'd be like, go be a PR person there.

Go be a junior account manager there.

Yeah, there's a cafeteria workers.

Yeah, you guys have a cafeteria.

You literally show up and you say, hey, I'm the best coffee bringer to your desk or ever.